Bayer AG CEO Bill Anderson's plans for a radical realignment of the company to reduce bureaucracy and increase efficiency have been bolstered by union backing in Germany for major management job cuts, but any proposals to break up its three-pillar structure of pharma, consumer health and crop science will likely meet with considerable opposition.
Bayer Secures Backing For Job Cuts But Not For Break-Up
The German major's works council has agreed to support a significant reduction in managerial jobs but is “vigorously campaigning” to ensure that the firm's three-division structure remains intact.
More from Strategy
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
More from Business
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.